Insiders who reported open-market trades in the last 12 months at the companies Michael James Newman files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Michael James Newman is a corporate insider, tracked as CSO and Director, Director of Indaptus Therapeutics, Inc. (INDP). InsiderAlpha holds 2 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
When did Michael James Newman last file a Form 4?
The most recent primary Form 4 on record is dated 29 December 2025, one of 2 filings going back to 2024.
Michael James Newman is CSO and Director, Director of Indaptus Therapeutics, Inc. (INDP). 2 SEC Form 4 filings on record going back to 2024, most recently on 29 December 2025.
Recent transactions
1
The latest SEC Form 4 transaction reported by Michael James Newman.
InsiderAlpha's records for Michael James Newman go back to 2024: 2 primary Form 4 filings, an average of 0.7 per year. No recorded transaction carries a Rule 10b5-1 plan flag. An absent flag does not establish whether a transaction was pre-arranged or discretionary.
